Skip to main content
SpringerLink
Log in

Recent R&D Highlights

  • News & View
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The EUREKA Initiative aims to strengthen European competitiveness by promoting cross-border, market-oriented, collaborative R&D. It enables industry and research institutes from 35 member countries and the EU to collaborate in a bottom-up approach to developing and exploiting innovative technologies.

  2. Early virologic response is defined as a >2 log (≥ 99%) reduction in HCV RNA viral load.

  3. This novel polymer was profiled in Pharmaceutical & Diagnostic Innovation 2005; 3 (7): 11–12.

  4. GelSite is the core polymer used in the GelVac nasal powder delivery system.

References

  1. Eureka. Turning the tables on drug discovery [online]. Available from: http://www.eureka.be/inaction/viewSuccessStory.do?.docid=1719838 [Accessed 2006 May 30]

  2. Eureka. Turning the tables on drug discovery. Media release: 24 May 2006

    Google Scholar 

  3. Novartis. Novartis strengthens infectious disease portfolio by acquiring rights to AlbuferonTM, a hepatitis C interferon drug set to enter phase III trials. Media release: 6 Jun 2006

    Google Scholar 

  4. Human Genome Sciences. Human Genome Sciences presents interim results of phase 2 trial of AlbuferonTM with ribavirin in patients with chronic hepatitis C who failed to respond to previous therapy. Media release: 1 May 2006

    Google Scholar 

  5. Human Genome Sciences. Human Genome Sciences presents interim results of phase 2b trial of AlbuferonTM with ribavirin in treatment-naïve patients with chronic hepatitis C. Media release: 1 May 2006

    Google Scholar 

  6. Human Genome Sciences. Change of price target. New York: Lehman Brothers Global Equity Research, 2006

    Google Scholar 

  7. Alnylam Pharmaceuticals. Alnylam receives issued U.S. patent broadly covering RNAi therapeutics. Media release: 6 Jun 2006

    Google Scholar 

  8. Carrington Laboratories. Carrington receives European patent protection for stabilization of proteins and peptides. Media release: 13 Jun 2006

    Google Scholar 

  9. Curis. Curis issued U.S. patent covering drug discovery assays. Media release: 13 Jun 2006

    Google Scholar 

  10. Iomai. Iomai Corporation awarded key vaccine technology patent. Media release: 13 Jun 2006

    Google Scholar 

  11. Sentigen. Sentigen announces issuance of patent. Media release: 8 Jun 2006

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 4, 14–16 (2006). https://doi.org/10.1007/BF03257081

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257081

Search

Navigation